A multi-national, randomised, double-blind, placebo-controlled, Phase II study to assess the efficacy and safety of three doses of sublingual immunotherapy administered as recombinant Bet v 1 tablets once daily to patients suffering from birch pollen rhinoconjunctivitis.

Trial Profile

A multi-national, randomised, double-blind, placebo-controlled, Phase II study to assess the efficacy and safety of three doses of sublingual immunotherapy administered as recombinant Bet v 1 tablets once daily to patients suffering from birch pollen rhinoconjunctivitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Birch pollen allergy immunotherapy (Primary)
  • Indications Hypersensitivity; Rhinoconjunctivitis
  • Focus Therapeutic Use
  • Sponsors Stallergenes SA
  • Most Recent Events

    • 04 Apr 2012 Official Title amended as reported by European Clinical Trials Database record.
    • 15 Mar 2012 Actual initiation date changed from Oct 2008 to Aug 2008 as reported by European Clinical Trials Database.
    • 15 Mar 2012 Actual end date (Mar 2009) added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top